Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Medro vs Vytora Health

Medro
Graded #252

Lower grade

vs+8.699999999999996
Vytora Health
Graded #79

Higher grade

The verdict

Vytora Health takes it — 72.3/100 to 63.6/100.

Vytora Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Vytora Health is a 50-state-plus-DC telehealth platform offering compounded semaglutide and tirzepatide alongside brand-name Mounjaro and Zepbound, plus NAD+ and sermorelin peptides.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueVytora Health +9
50
59
Dose & formulationVytora Health +8
77
85
Clinical oversightVytora Health +25
71
96
Labs & monitoringVytora Health +3
52
55
FulfillmentVytora Health +4
92
96
Contract termsMedro +13
33
20
Medro · left barVytora Health · right bar

The numbers

MetricMedroVytora Health
WeighScore63.6/10072.3/100
GradeCC
Scorecard rank#252#79
Semaglutide$199/mo (compounded)$180/mo (all doses, compounded)
Tirzepatide$299/mo (compounded)$249/mo (all doses, compounded)
CoverageAll 50 statesAll 50 states
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
Medro

Graded #252 · C

Strengths

  • Covers both compounded semaglutide and tirzepatide and can prescribe brand-name GLP-1s when clinically appropriate.
  • LegitScript-certified (seal #50716646), available in all 50 states, with tiered pricing shown before checkout.
  • No membership fee and free expedited shipping on all orders; online intake with no appointment required in many cases.
  • Prices drop with longer commitments (semaglutide to $149/mo, tirzepatide to $224/mo on a 12-month plan).

Where it loses points

  • Does not name its compounding pharmacy or its clinical partner medical group, so the fulfillment chain is not verifiable.
  • Pricing is described as illustrative and may change by dose, pharmacy availability, and eligibility — final cost shows only at checkout.
  • Very new brand (2026, trademark pending) spanning many verticals, with a short track record in GLP-1 care.
  • Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.
Vytora Health

Graded #79 · C

Strengths

  • All 50 states plus DC, with per-state video-vs-audio compliance disclosed
  • Both compounded and brand-name options on one platform — uncommon
  • LegitScript Approved and HIPAA compliant
  • Pharmacy partners named publicly: Vials Pharmacy (TX) and Greenwich Biosciences
  • Operating entity disclosed: Wasef Health, PC (Pinellas Park, FL)

Where it loses points

  • Brand-name Mounjaro/Zepbound at $1,399/mo is near retail — insured patients may do better via LillyDirect Self Pay ($449-$699/mo)
  • Compounded tirzepatide at $249/mo is mid-market, above the $149-199 floor
  • Dose tiers aren't broken out — 'all doses included' means low-dose patients pay the same as high-dose
  • Initial consultation cost not shown on the public pricing page
  • Limited per-prescriber state licensure detail

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard